Parallel distribution is defined as the distribution of a centrally authorised medicinal product from one Member State to another by a pharmaceutical company independent of the marketing authorisation holder.
This ATP brings changes to the labelling and classification of some existing harmonized substances and adds new harmonized substances in Part 3 of Annex VI.
Contact us if you need to be assured that your translations intended for healthcare professionals and patients are prepared by experts understanding the implications behind and medical language